Translational Oncology
- Biomarker discovery
- Human tumor bank
- Mouse clinical trial
- 67 PDX-derived primary cancer cell lines
- Drug-resistant PDX models
- Combination therapy platform including radiation
- World leading genome sequencing and bioinformatics capability
In Vitro Pharmacodynamic Capability
- ELISA (enzyme-linked immunosorbent assay)
- Western blotting
- Regular PCR and qPCR (real-time quantitative PCR)
Biomarker Discovery with IHC (immunohistochemistry)
- Instrument platforms:1)Automated Station/Leica Autostainer XL. 2)Vectra, PerkinElmer (caliper). 3)Fluorescence Microscope/Axio Imager A2 & Nikon NI-U
- Opal multiplex IHC platform
DNA FISH Assay
- DNA FISH technique and its clinical application
- Workflow of DNA FISH
- HER2, EGFR, and other FISH on FFPE slides
- DNA FISH on blood sample
Combination Therapy Platform including Radiation
Radiation baseline in syngeneic models
- Radiation was recently considered to be promising in combination with immunotherapy, based on its capacity of mobilizing immune responses
- RadSource RS2000/XE X-ray irradiator suitable for small animal use
- 2 syngeneic models with radiation therapy data
Radiation baseline in PDX models
- 21 PDX models with radiation therapy data
Case study: combination therapy with radiation
- Breast cancer model: BR-05-0028
- MLN4924, a NAE inhibitor, showed synergetic effect with focal radiation
PDX Derived Human Cancer Cell Lines (PCC)
67 human cancer cell lines generated from PDX models
- With matched PDX models
- Cancer stem cell (CSC) features
- 64/67 form xenografts in mice which recapitulate pathology of the original patient tumor
- Genomic profiling data available
Drug-resistant PDX
- Resistance was induced by repeated treatment
- Genomic profiling data available for erlotinib and crizotinib resistant NSCLC models
Erlotinib Resistant Lung Cancer PDX Harboring EGFRL858R
- LU-01-0055 PDX harboring EGFRL858R
- Sensitive to erlotinib
- Erlotinib resistant LU- 01-0055R
- Afatinib overcame the erlotinib resistance
Innovative Translational Research Platform
Learn more about our Innovative Translational Research Platform.